MedTrace Logo

Deep Phenotyping of Cutaneous Lupus Erythematosus

NCT06411106 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-05-13

No results posted yet for this study

Summary

Cutaneous lupus erythematosus (CLE) is an autoimmune disease of which the pathogenesis and pathophysiology are not fully understood. Given the complex and heterogeneous character of the disease, identification, and development of specific biomarkers for diagnosis, disease subtyping, disease severity, and treatment response in CLE is challenging. Therefore, the main objective of the current study is to further characterize CLE by using a deep phenotyping approach. Moreover, the role of TLR7 activation in the pathophysiology of the various clinical subtypes of CLE will be specifically studied. With this approach the investigators aim to characterize objectively measured disease characteristics and detect novel biomarkers for CLE(-subtypes).

Conditions

  • Cutaneous Lupus Erythematosus

Interventions

DRUG

IMIQUIMOD cream 50mg/g

5 mg imiquimod (100mg Aldara®) per treatment site with a 12mm Finn chamber

Sponsors & Collaborators

  • Centre for Human Drug Research, Netherlands

    lead OTHER

Principal Investigators

  • R. Rissmann, RPh, PhD · Centre for Human Drug Research

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2025-09-30
Completion
2025-09-30

Countries

  • Netherlands

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06411106 on ClinicalTrials.gov